<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964988</url>
  </required_header>
  <id_info>
    <org_study_id>AK-2016-PC-1</org_study_id>
    <secondary_id>2016-002184-34</secondary_id>
    <nct_id>NCT02964988</nct_id>
  </id_info>
  <brief_title>uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer</brief_title>
  <official_title>uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the applicability of urokinase plasminogen
      activator receptor (uPAR) Positron Emission Tomography (PET) / CT molecular imaging in
      patients with metastatic castration-resistant prostate cancer (mCRPC)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      68Ga-NOTA-AE105 is a radioligand targeting urokinase plasminogen activator receptor (uPAR),
      which is a promising imaging biomarker of tumor aggressiveness. 68Ga-NOTA-AE105 PET/CT will
      be applied in patients with mCRPC during treatment with Radium-223. PET/CT will be performed
      before initiation of Radium therapy and after two treatment cycles. The initial
      semiquantitative uptake (standard uptake values, SUVs) of 68Ga-NOTA-AE105 in metastases as
      well as the change in these parameters after therapy will be correlated with overall survival
      and progression free survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>uPAR PET/CT imaging</measure>
    <time_frame>1 hour post injection</time_frame>
    <description>Standard uptake values (SUVs) of 68Ga-NOTA-AE105 evaluated on uPAR-PET/CT scan performed within 1 hour following injection of 68Ga-NOTA-AE105</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in uPAR PET/CT after two cycles of Radium-223</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in Standard uptake values (SUVs) of 68Ga-NOTA-AE105 evaluated on uPAR-PET/CT scan performed after 2 cycles of Radium-223 therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>uPAR PET/CT as prognostic factor for overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>Patients will be followed for 12 months after uPAR PET/CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>uPAR PET/CT as prognostic factor for progression free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Patients will be followed for 12 months after uPAR PET/CT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>uPAR PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 68Ga-NOTA-AE105 followed by PET/CT scan. Administration will be performed twice in approximately 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection of PET tracer 68Ga-NOTA-AE105</intervention_name>
    <description>Following injection of 68Ga-NOTA-AE105 the patients will be subjected to whole body PET/CT</description>
    <arm_group_label>uPAR PET/CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/CT</intervention_name>
    <description>Whole body PET/CT</description>
    <arm_group_label>uPAR PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic castration resistant prostate cancer

          -  Approved to receive Radium-223 therapy

          -  Written and oral consent

        Exclusion Criteria:

          -  Lack of communication skills

          -  Other known malignant disease

          -  Known allergy towards IMP

          -  Severe claustrophobia

          -  If a participant exhibits allergic reaction i the IMP, the participant will be
             excluded from further participation in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Fosboel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine &amp; PET</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Fosboel, MD</last_name>
    <phone>+45 31508808</phone>
    <email>marie.oebro.fosboel@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Kjaer</last_name>
    <phone>+4535454011</phone>
    <email>akjaer@sund.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Fosboel, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2016</study_first_submitted>
  <study_first_submitted_qc>November 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>January 4, 2017</last_update_submitted>
  <last_update_submitted_qc>January 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Marie Øbro Fosbøl</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

